A Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumor Patients
Status: WITHDRAWN
Study type: INTERVENTIONAL
Conditions: Non Small Cell Lung Cancer|Advanced Triple Negative Breast Cancer|Small Cell Lung Cancer|Urothelial Cancer|Mesothelioma|Malignant Melanoma
Interventions: DRUG: Pembrolizumab|BIOLOGICAL: CDX-1401|BIOLOGICAL: Poly-ICLC
Sponsor: Case Comprehensive Cancer Center